In the treatment of intermittent asthma, what is the recommended approach?

For the treatment of intermittent asthma, the recommended approach is to use a short-acting beta-agonist (SABA) as needed for symptom control. This is because intermittent asthma is characterized by symptoms that occur less than twice a week, and the use of SABAs is effective for quick relief during these occasional episodes. SABAs work by relaxing the muscles around the airways, leading to dilation and easing breathing.

Daily controller medications, such as inhaled corticosteroids or long-acting beta agonists, are typically advised for more persistent asthma conditions. These options are intended to prevent symptoms and manage chronic airway inflammation; however, they are not necessary for intermittent asthma, where symptoms are infrequent and can be managed with as-needed SABA use.

Inhaled corticosteroids are primarily considered for persistent asthma as a first-line treatment to reduce airway inflammation and frequency of exacerbations but are not appropriate for individuals with intermittent patterns of symptoms.

Similarly, long-acting beta agonists serve a supportive role in controlling more persistent forms of asthma and are not meant for intermittent symptom management. They should also be prescribed alongside inhaled corticosteroids to ensure a comprehensive chronic management strategy.